INC Research, inVentiv merger 'a perfect fit'

By Melissa Fassbender contact

- Last updated on GMT

As a single company, INC and inVentiv will offer end-to-end solutions to support drug development and commercialization. (Image: iStock/AndreyPopov)
As a single company, INC and inVentiv will offer end-to-end solutions to support drug development and commercialization. (Image: iStock/AndreyPopov)

Related tags: Inventiv health, Chief executive officer, Executive officer, Corporate governance

INC Research and inVentiv Health are merging to create one of the largest biopharmaceutical outsourcing providers – and a “top three CRO,” says CEO.

As a single company, the new entity will be made up of more than 22,000 employees across more than 60 countries, and will be able to serve customers in more than 110 countries.

We’re in in a business where scale counts – and this makes us a top three CRO​,” Alistair Macdonald, Chief Executive Officer (CEO) of INC Research, told Outsourcing-Pharma.com. “[The merger] gives us the scale that we need in all different countries around the world​.”

Michael Bell, CEO of inVentiv Health echoed the sentiment, telling us the company identified the need to gain scale and increase its global presence early on – and INC is “a perfect fit​” for inVentiv’s deficiencies. 

It’s about as good of a fit that we could have hoped for, and really unique in the industry​,” Bell said.

Concurrently, Macdonald explained the merger gives the companies the ability to deliver different models – including full service, hybrid, and FSP – to any size company in any country.

The new biopharmaceutical solutions organization, which will be headquartered in Raleigh, NC, will have combined net revenue of more than $3.2bn and a combined enterprise value of approximately $7.4bn.

Integration

As Macdonald explained, the companies are looking to bring the best of both INC Research and inVentiv to the newly combined organization, though integration will be difficult because of the scale.

The challenge is not to be underestimated​,” he added, “but it’s something we have a lot of experience with​.”

While overlapping roles are to be expected, and some functions will be able to be consolidated, the companies currently have no firm plans as it pertains to restructuring.

The transaction is expected to be completed in the second half of 2017 at which time Macdonald will become CEO of the combined company and Bell will serve as executive chairman.

The combined Board of Directors will consist of 10 directors, five designated by each respective company, including both Macdonald and Bell.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars